Understanding the mechanisms involved in producing immune responses against cancer following radiotherapy, as well as how activation or inhibition of key players involved in cGAS–STING signaling affects antitumor efficacy, will aid in informing strategies to improve radiotherapy. The gene discussed is STING1; the disease is cancer.